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Abstract
All gammaherpesviruses encode a major glycoprotein homologous to the Epstein-Barr virus gp350. These glycoproteins are
often involved in cell binding, and some provide neutralization targets. However, the capacity of gammaherpesviruses for
long-term transmission from immune hosts implies that in vivo neutralization is incomplete. In this study, we used Bovine
Herpesvirus 4 (BoHV-4) to determine how its gp350 homolog - gp180 - contributes to virus replication and neutralization. A
lack of gp180 had no impact on the establishment and maintenance of BoHV-4 latency, but markedly sensitized virions to
neutralization by immune sera. Antibody had greater access to gB, gH and gL on gp180-deficient virions, including
neutralization epitopes. Gp180 appears to be highly O-glycosylated, and removing O-linked glycans from virions also
sensitized them to neutralization. It therefore appeared that gp180 provides part of a glycan shield for otherwise vulnerable
viral epitopes. Interestingly, this O-glycan shield could be exploited for neutralization by lectins and carbohydrate-specific
antibody. The conservation of O-glycosylation sites in all gp350 homologs suggests that this is a general evasion
mechanism that may also provide a therapeutic target.
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Introduction
Epstein-Barr virus (EBV) and Kaposi’s Sarcoma Associated
Herpesvirus (KSHV) are DNA tumor viruses that provide risk
factors for Burkitt’s lymphoma, Hodgkin’s lymphoma, nasopha-
ryngeal carcinoma, Kaposi’s Sarcoma and post-transplant lym-
phoproliferative disease [1–2]. EBV infection has also been
associated with multiple sclerosis [3–4]. Healthy carriers consis-
tently shed virus in saliva [5] that infects naı ¨ve individuals [6–7]
despite being exposed to virus-specific antibody [8–9]. This lack of
neutralization contrasts completely with non-persistent mucosal
infections such as that of poliovirus [10–11], and implies that
gammaherpesviruses have evolved specific antibody evasion
mechanisms.
Neutralizing antibodies generally target epitopes involved in
virion binding or membrane fusion [12]. Targeting of the gB/gH/
gL [13–16] fusion machinery [17–18] seems to be limited by a
paucity of good targets [19] and poor immunogenicity [20].
Therefore most studies have looked at binding. The EBV gp350 is
an abundant component of the virion envelope that binds to
CD21 on B cells [21–22] and is a target for antibodies that
neutralize B cell infection [23]. However, while EBV lacking
gp350 is poorly infectious for B cells [24–25], it infects CD21-
negative epithelial cells better than the wild-type [25], and these
may provide a primary target for virions entering naive hosts.
Epithelial infection can even be enhanced by gp350-specific
antibodies [26]. Therefore the relationship between EBV
transmission, gp350, and gp350-specific antibodies needs further
exploration, particularly as gp350 is a candidate EBV vaccine [27–
28].
Our understanding of EBV and KSHV is limited by their
narrow species tropisms. Related animal viruses are therefore an
important source of information. Two of the best established
experimental models are provided by Murid herpesvirus 4
(MuHV-4) [29] and Bovine herpesvirus 4 (BoHV-4) [30–31].
Their homologs of gp350 are gp150 in MuHV-4 [32], encoded by
M7, and gp180 in BoHV-4 [33], encoded by Bo10. While these
proteins are diverse in sequence, they seem to be related in
function, being involved in both binding to a cellular receptor and
in blocking the infection of cells that do not express this receptor
[25,32–33]. It has been proposed that the receptor interaction
displaces each homolog to reveal other glycoproteins involved in
entry. Thus, a non-essential glycoprotein [24,32–33] could hide
from neutralization some critical epitopes on cell-free virions.
To date, the in vivo function of gp350 homologs has only been
investigated with MuHV-4. Surprisingly, gp150-deficient viruses
showed only a transient lag in lytic replication in vivo and
established normal levels of latency [32]. Gp150 is the most
immunogenic MuHV-4 glycoprotein and anti-gp150 antibodies
play a predominant role in driving Fc receptor-dependent
PLoS Pathogens | www.plospathogens.org 1 November 2011 | Volume 7 | Issue 11 | e1002387infection [20]. While gp150 does not have an obvious direct role in
cell-binding, BoHV-4 lacking gp180 displays a binding deficit
[33]. Therefore this protein may be more closely analogous to
gp350 and the KSHV K8.1 than is gp150. Here we investigated
the consequences of gp180 deletion for BoHV-4 replication in vivo
and neutralization. An important gp180 function seemed to be to
block the binding to virions of antibodies that would otherwise
neutralize.
Results
Generation of a Bo10 nonsense BoHV-4 mutant
We previously described a BoHV-4 strain in which the entire
Bo10 ORF was replaced by an eGFP expression cassette [33].
Since expression cassettes can cause in vivo attenuation, we also
generated a second Bo10 mutant virus, in which stop codons
terminated Bo10 translation 7 amino acids before the end of its
predicted signal sequence without any associated deletion
(Figure 1A). A revertant strain, called Bo10 STOP Rev, was
finally constructed to validate the Bo10 STOP mutant. The
predicted molecular structures of the recombinant strains were
confirmed by EcoRI restriction mapping and Southern blotting
(Figure 1B), and further by DNA sequencing. Immunoblotting
with an anti-Bo10-c15 rabbit polyserum [33] established that the
Bo10 mutant virions lacked gp180 (Figure 1C).
Dissemination of Bo10- mutants in vivo
To investigate the importance of Bo10 in vivo, we infected
rabbits with the different viral strains as described in the Material
and Methods. No rabbit showed clinical disease or noticeable
pathology at necropsy 64 days post-inoculation. Host colonization
was assayed by quantitative PCR of DNA from peripheral blood
mononuclear cells (PBMC) over time (Figure 2A and B) and from
the spleens at 64 days post-inoculation (Figure 2C and D). The
Bo10 mutants showed no deficit. We further performed infectious
center assays on spleen cells from the WT and Bo10 STOP
infected rabbits. Viral plaques were observed in all samples
(Figure 2E). No preformed infectious virus was detected in the
equivalent freeze-thawed samples (data not shown), so this was
latent infection. Thus, we detected no difference in acute
replication, latency establishment or reactivation of Bo10-deficient
mutants compared to WT or revertant strains.
Increased susceptibility of Bo10- BoHV-4 to serum
neutralization
While pathogenesis assays are a useful measure of viral fitness,
they do not measure all viral functions. In particular, virion
susceptibility to neutralization [33] might not be measured
because intra-host dissemination depends mainly on cell/cell virus
spread and latency-associated cell proliferation. We therefore
further compared the sensitivity of BoHV-4 WT, Bo10 Del, Bo10
Rev and Bo10 STOP strains to neutralization by sera of rabbits
infected with the BoHV-4 V.test strain (Figure 3). WT and Bo10
Rev virions were poorly neutralized. Bo10 Del and Bo10 STOP
virions were neutralized much better. In particular, complete
neutralization was now possible. Neutralization experiments with
eGFP expressing viruses on different cell types confirmed this
result, with gp180-deficient virions showing increased sensitivity to
neutralization by anti-BoHV-4 serum compared to WT virions
(Figure S1). Thus gp180 seemed to limit virion neutralization.
Bo10 sequence variation
In order to understand how gp180 might protect virion against
neutralization, we compared the Bo10 genes of different BoHV-4
isolates [34]. All showed consensus splice donor and acceptor sites
that are used in the BoHV-4 V.test strain to generate gp180 [33].
Nucleotide sequences comparison across the entire open reading
frames revealed up to 15% inter-strain divergence (Table S1).
Amino acid divergence between American-European and African
strains reached 39%, mostly in the N-terminal half of the protein
ectodomain (Figure 4A). By comparison, gB, gH and gL differ by
,2% between KSHV strains [35]; gB differs by ,2% between
OHV-2 strains [36]; and ORF71 differs by only 5% between
BoHV-4 strains. All gp180s were extremely rich in serine and
threonine residues, which accounted for 54.3 +/2 0.6% of each
mature ectodomain (Figure 4A). Asparagine residues accounted for
a further 8.0 +/2 0.6%. Therefore, a conserved feature seemed to
be extensive O- and N-linked glycosylation (Figure 4A–C) [37].
Gp180 is O-glycosylated
T h eB o 1 0g e n ep r o d u c to fB o H V - 4V . t e s th a s1 2 2a n d7p o t e n t i a l
O- and N-glycosylation sites respectively (Figure 4) [37]. This protein
has a predicted molecular mass (MM) of 25 kDa but an apparent
MM of 180 kDa [33]. To establish the contribution of glycans to the
apparent MM, we digested virions lysates with glycanases. We
removed high mannose, hybrid and complex N-glycans [38] with
PNGaseF.We removed O-glycanssuccessivelywithsialidaseA,b1-4
Galactosidase and O-glycanase. While PNGase F did not affect the
apparent MM of gp180 (Figure 5A), removing O-glycans reduced it
to approximately20 kDa, consistent with its predicted unglycosylated
MM. Therefore, gp180 was extensively O-glycosylated and O-
glycans appear to account for most of its mass.
Glycans protect BoHV-4 against neutralization
To test whether O-glycans protect BoHV-4 against neutraliza-
tion, we removed N- and/or O-glycans from intact virions before
testing their susceptibility to neutralization. As removing glycans
itself could affect viral titers (Figure S2), we expressed the results as
a percentage of the number of plaques for each treatment without
neutralization. As observed for other viral species [39–41],
removing N-glycans increased virion susceptibility to neutraliza-
tion by immune serum (Figure 5B). Removing O-glycans had a
similar effect (Figure 5B). Therefore BoHV-4 uses both N- and O-
linked glycans to limit its neutralization. Interestingly, gp180 bears
most of the predicted BoHV-4 envelope O-glycans (122/155) [37].
These results suggest therefore that gp180 O-glycans provide part
of a glycan shield for otherwise vulnerable viral epitopes.
Altered antigenicity of BoHV-4 lacking gp180
Our subsequent analysis focused on the identification of the
neutralization epitopes hidden by gp180. The MuHV-4 gp150
Author Summary
Herpesvirus transmission between immune hosts implies
some kind of antibody evasion. However, the underlying
molecular mechanisms remain largely unknown. All gam-
maherpesviruses encode a major glycoprotein homologous
to the Epstein-Barr virus (EBV) gp350. Gp350 binds EBV to B
cells and provides a neutralization target. However, despite
its immunogenicity, EBV carriers remain infectious. Here we
show that the gp350 homolog of the related Bovine
Herpesvirus 4 (BoHV-4), gp180, and its O-glycans, shield
some otherwise vulnerable viral epitopes. Extensive O-
glycosylation is common to all gammaherpesvirus gp350
homologs, suggesting that this evasion mechanism is also
widespread.
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PLoS Pathogens | www.plospathogens.org 2 November 2011 | Volume 7 | Issue 11 | e1002387Figure 1. Generation of a Bo10 STOP BoHV-4 mutant. A. Schematic representation of the strategy followed to produce the recombinant
BoHV-4 strains. The Bo10 STOP BoHV-4 mutant was derived from a cloned BoHV-4 BAC by galK-counterselection method. The Bo10 coding sequence
was disrupted by inserting stop codons near the end of the coding sequence for its predicted signal peptide (Bo10 STOP). The mutation incorporated
two BamHI and one EcoRI restriction sites. B. Verification of the molecular structure. Viral DNA was digested with EcoRI, resolved by agarose gel
electrophoresis, and hybridized with a
32P-labeled probe, corresponding to nucleotides 65,696–66,595 of the BoHV-4 V.test strain genome. Black
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[42]. We therefore focused on antibodies raised against the BoHV-
4 gB, gH and gL. Monoclonal antibodies (mAbs) were screened for
gB, gH, gL or gH/gL specificity as described in the Material and
Methods. Mabs 16, 29 and 33 recognize gL, gB and the
heterodimer gH/gL, respectively (Figure S3). Mab 35 recognizes
gB as previously stated [43].
As with MuHV-4 [32], infected cell surfaces provide a means of
probing antigenic differences between BoHV-4 glycoprotein
mutants. We compared cells infected by WT, Bo10 Del, Bo10
Rev, WT BAC, Bo10 STOP and Bo10 STOP Rev BoHV-4
viruses. MAbs 29 and 35 (recognizing gB), mAb 16 (recognizing
gL) and mAb 33 (recognizing the gH/gL complex) all stained cells
infected with the Bo10 Del and Bo10 STOP strains better than
they stained those infected with wild-type or revertant viruses
(Figure 6). This result was not due to differences in protein
expression, as permeabilized cells gave similar staining with each
virus (Figure 6).
Figure 2. In vivo persistence of Bo10- mutants. Groups consisting of 3 rabbits were mock-infected or infected with 10
8 PFU of BoHV-4 WT V.test,
Bo10 Del and Bo10 Rev strains (A and C) or infected with 10
7 PFU of BoHV-4 WT V.test and Bo10 STOP excised strains (B, D and E). A–D. Real-Time PCR
relative quantification of BoHV-4 genomes. DNA was extracted from the PBMC (A and B) at the different times post-inoculation and from the spleen
(C and D) 64 days post-inoculation. Data are expressed as the number of BoHV-4 ORF8 gene copies per 100 ng of total DNA. In A and B, the data
presented are the average 6 SEMs and were analyzed by 2ways ANOVA and Bonferroni posttests. In C and D, each point shows the genome copies
for one rabbit. The data were analyzed by 1way ANOVA and Bonferroni posttests or Student t-test. No significative difference was observed. E.
Spleens from the different rabbits were analyzed individually for reactivable BoHV-4 by infectious-center assay. Each point shows the infectious
centers for one rabbit. The data were analyzed by Student t-test. No significative difference was observed.
doi:10.1371/journal.ppat.1002387.g002
triangle shows the restriction fragment that contains the WT Bo10 gene. The Bo10 Del fragment is higher due to eGFP insertion [33], however, it is
much less visible due to deletion of most of the ORF. The 16,882-bp wild-type (WT) band becomes 14,033-bp (open triangle) for the Bo10 STOP
mutant. The 2,885 bp band is not visible because it only hybridizes with a few nucleotides of the probe. In WT BAC, Bo10 STOP BAC and Bo10 STOP
BAC Rev strains, the 4,870 bp band becomes 9,964 bp and 3,416 bp due to BAC cassette insertion as described previously [30]. Marker sizes in Kbp
are indicated on the left. C. Detection of the Bo10 encoded gp180 protein by the anti-Bo10-c15 serum. Purified virions (5*10
5 virions per lane) were
subjected to western blotting with anti-Bo10-c15 serum as described in the Material and Methods. The position of a molecular mass (MM) standard
(in kDa) is shown on the left.
doi:10.1371/journal.ppat.1002387.g001
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labeling with mAb 35 raised against gB. While binding of gold
particles was observed with both strains (Figure 7A), there were
statistically more particles on Bo10 Del virions than on WT virions
(p,0.001). Representative particules are shown in Figures 7B and
S4. This difference did not reflect a greater gB content of Bo10 del
virions, since immunoblotting on the same viral preparations with
the same antibody showed equivalent signals between the mutant
and the WT (Figure 7C). The different stocks displayed also
similar particle/PFU ratios as shown in Figure 7D. Finally,
increased accessibility of some epitopes on Bo10 mutant virions
was confirmed by immunofluorescence (Figure 7E) of virions
bound to cell surfaces. The cells were scanned by confocal
microscopy with settings unchanged between different viruses
stained with the same antibody. Glow pseudo-color analysis
established that the staining was stronger when Bo10 was deleted.
The difference was particularly evident for mAbs 16 (anti-gL) and
33 (anti gH/L) (Figure 7E). Together these results established that
gB, gL and gH/L epitopes were more accessible on Bo10 mutant
virions than on WT or revertant viruses, consistent with gp180
hiding key epitopes from neutralization.
Increased susceptibility of Bo10- BoHV-4 to gL directed
neutralization
We next tested whether mAbs recognizing Bo10 mutants better
(Figure 6 and 7) could also neutralize them better than WT or
revertant virions. While mAbs 29, 35 (anti-gB) and 33 (anti-gH/L)
did not neutralize any strain (data not shown), mAb 16 (anti-gL)
neutralized the Bo10 mutants better in different cell types
(Figure 8A, Figure S5). It was not possible to achieve complete
neutralization as it had been with immune sera (Figure 8B).
Therefore, gL is likely to be only one of several neutralization
targets protected by gp180 or other protection mechanisms exist.
However, it was clearly one such target, establishing that the
reduction in gL accessibility by gp180 was functionally important.
Immunogenicity of BoHV-4 lacking gp180
The results obtained above showed that removal of gp180
results in the unmasking of several viral envelope epitopes among
which some neutralization targets. To test whether gp180 might
also affect BoHV-4 immunogenicity, we compared the humoral
immune response induced in the rabbits by the Bo10 STOP strain
to that observed with the wild type parental strain (Figure 9). Over
the course of infection, no difference in total anti-BoHV-4
antibody response was observable between the groups of infected
rabbits (Figure 9A). However, as the anti-herpesvirus antibody
response is often dominated by capsid proteins, some subtle
changes could be masked. We therefore investigated specific
responses against gB, gH and gL. 293T cells expressing GPI-linked
forms of gL, the gB extracellular domain or the gH extracellular
domain, were stained with anti-BoHV-4 WT sera or with anti-
BoHV-4 Bo10 STOP sera. The results obtained showed that sera
of both groups of rabbits stained similarly gB and gH, whereas no
detectable gL staining was observed (Figure 9B) although specific
monoclonal antibodies confirmed cell surface expression of all
proteins (data not shown). Finally, we compared the neutralization
potential of these sera against WT, Bo10 Del, Bo10 STOP or
Bo10 Rev virions. As observed previously for anti-BoHV-4 WT
serum, anti-BoHV-4 Bo10 STOP serum neutralized Bo10 mutant
viruses better. However, no significative difference in neutraliza-
tion potential was observable between both groups of serum
(Figure 9C). Our results suggest therefore that gp180 deficient
virions display enhanced susceptibility to neutralizing antibodies
but do not elicit markedly enhanced antibody response in infected
rabbits. Thus, antigenicity does not predict immunogenicity.
Gp180 O-glycans can be a target for neutralization
While O-glycans help BoHV-4 to evade neutralizing antibodies,
they can potentially be targeted by carbohydrate binding agents,
as proposed for other viruses. Gp180 is not essential for BoHV-4
replication, but lectins could still compromise virus entry by steric
hindrance. We therefore tested the capacity of jacalin, an O-
glycan-specific lectin, to inhibit BoHV-4 infection (Figure 10A).
Inhibition was evident for WT and Bo10 Rev virions, whereas
Bo10 deleted virions were relatively resistant. Therefore O-glycan-
directed neutralization was possible for BoHV-4 and appeared to
target mainly gp180.
Another strategy would be to use specific antibodies, much as
HIV can be neutralized by an antibody that binds to the high-
mannose glycans of its gp120 ‘‘silent face’’ [44]. In animals apart
from humans, apes and Old World monkeys, the a1-3-
galactosyltransferase enzyme adds a terminal galactose onto
glycoproteins and glycolipids in a specific a1-3 linkage to generate
the Gal epitope [45]. We have previously shown that human sera
consequently exhibit innate BoHV-4 neutralization through
complement activation by anti-Gal antibodies [46]. We therefore
compared the sensitivity BoHV-4 WT, Bo10 Del, Bo10 Rev and
Bo10 STOP virions to anti-Gal dependent neutralization. While
complement-containing horse serum supplemented with anti-Gal
antibodies neutralized WT and Bo10 Rev virions in a dose-
dependent manner, Bo10 Del and Bo10 STOP virions were only
slightly affected (Figure 10B). Thus gammaherpesvirus glycan
shields are potentially accessible to neutralization by carbohydrate-
specific antibodies.
Discussion
Persistent viruses must evade multiple arms of the host immune
response to maintain infectivity [47–48]. Gammaherpesviruses are
archetypal persistent viruses, and their cytotoxic T cell evasion
mechanisms are well-known [49–51]. Much less is known about
how they evade neutralizing antibodies. Gammaherpesviruses all
share a major glycoprotein homologous to EBV gp350. EBV
Figure 3. Neutralization of the BoHV-4 Bo10 mutants. BoHV-4
WT V.test, Bo10 Del, Bo10 Rev and Bo10 STOP virions were incubated
with sera of 4 different rabbits infected with BoHV-4 V.test strain. After
incubation (2 h, 37uC) the viruses were plaque assayed for infectivity on
MDBK cells. BoHV-4 titers are expressed relative to virus without
antibody. The data presented are the average 6 SEMs for 4
measurements and were analyzed by 2way ANOVA and Bonferroni
posttests, * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.ppat.1002387.g003
BoHV-4 gp180 Glycan Shield
PLoS Pathogens | www.plospathogens.org 5 November 2011 | Volume 7 | Issue 11 | e1002387Figure 4. Sequence analysis of the Bo10 encoded proteins of nine BoHV-4 strains. A. BoHV-4 Bo10 encoded proteins alignment. Predicted
Bo10 transmembrane protein encoded by nine different BoHV-4 strains were aligned (ClustalX; [88]). Predicted peptide signals [89] and
transmembrane regions were highlighted in pale and dark grey respectively. Non-conserved residues were printed in red. Serine (S) and threonine (T)
residues of the N-terminal ectodomain were highlighted in orange, asparagine (N) residues of the N-terminal ectodomain were highlighted in green.
Open and filled circles indicate potential O- and N-glycosylation sites respectively (using NetNglyc 1.0 and NetOglyc 3.1 algorithms [37]) that are
predicted for each of these residues in all the different strains that display such residue at that position. B. Prediction of N-glycosylation sites for the
complete BoHV-4 V.test gp180 protein sequence using the NetNglyc 1.0 algorithm. The shaded regions indicate the signal peptide and
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serum and saliva [52–55]. Moreover immunization with gp350
fails to reduce either infection rates or virus shedding [27–28].
Therefore, we still have much to learn about the interplay between
gp350, gp350-specific antibodies and EBV host entry. For
example, the inhibition of B cell infection by gp350-specific
antibodies [54,56] could have limited relevance to host entry, or
even promote it by enhancing epithelial infection [26]. Similarly,
antibodies to the MuHV-4 gp150 strongly enhance infection via
IgG Fc receptors [57]. Here we showed that BoHV-4 gp180 is
dispensable for establishment and maintenance of latency in vivo
(Figure 2), but drastically reduced the susceptibility of BoHV-4
virions to neutralization by immune serum on various cell types
(Figure 3, Figure S1). Gp180 seemed to hide at least partially
several different epitopes on gB, gH and gL (Figures 6, 7 and S4),
which included neutralization targets (Figures 8 and S5). Gp180 is
extensively O-glycosylated and O-glycans account for most of its
mass (Figures 4 and 5). These results suggest therefore that gp180
O-glycans provide part of a glycan shield for otherwise vulnerable
viral epitopes. Since extensive O-glycosylation is a common
feature of gammaherpesvirus gp350 homologs, this evasion
mechanism may be widely shared. Another common feature of
some of these proteins is strong immunogenicity [20,23,58]. The
reason is not fully understood, however if gp180 homologs shield
other virion glycoproteins, their location at the viral surface could
favor development of an antibody response against them.
The substantial gp180 divergence between different BoHV-4
strains (Table S1, Figure 4A) remains to be explained. It is possible
that much of the protein does not require a very specific amino
acid sequence for its function. Thus, a key feature of the gp350
homologs of different gammaherpesviruses may simply be that
they are type I transmembrane proteins with extensive O-
glycosylation [33] (Figures 4 and 5A). An importance of glycans
for immune evasion has also been hypothesized for gp350 [59].
Similarly, the HIV gp120 [60] uses glycans to provide a ‘‘silent
face’’ protected against most antibodies [41]. Thus while
neutralization is possible [61–62], this and other mechanisms
ensure that it is difficult. The Ebola virus glycoprotein (EBOV GP)
- again involved in virus binding [63] and a target for vaccine
design - is also extensively glycosylated and in this way partially
protected against antibody [64]. As with gp180, different
filoviruses show huge glycoprotein diversity but retain the basic
protein organization and extensive glycosylation [64]. This
immune evasion mechanism appears therefore to be shared by
several viral families.
While carbohydrates on SIV and HIV envelope proteins can
shield these viruses from antibody recognition and neutralization
[41,65], it appears that these glycans could also limit the
neutralizing antibody response in the context of SIV infection
[66] or HIV immunization [67]. We did not observe an increased
BoHV-4 immunogenicity in the absence of gp180 (Figure 9).
While most of the epitopes hidden by the gp120 glycan shield are
Figure 5. Glycosylation of BoHV-4 gp180 and importance of BoHV-4 glycans in neutralization evasion. A. Purified BoHV-4 WT V.test
strain virions were deglycosylated after denaturation. /, no enzyme; N-, protein N-glycanase; O-, sialidase A + b1-4 Galactosidase + O-glycanase; N O-,
protein N-glycanase + sialidase A + b1-4 Galactosidase + O-glycanase. Each was then immunoblotted for gp180 with anti-Bo10-c15 serum as
described in the Material and Methods. The position of a MM standard (in kDa) is shown on the left. B. Intact MDBK cell-derived BoHV-4 V.test strain
WT virions were deglycosylated without denaturation. /, no enzyme, N-, protein N-glycanase, O-, sialidase A + O-glycanase, N-O- protein N-glycanase
+ sialidase A + O-glycanase. Each was then tested for neutralization by serum of rabbits immunized by the BoHV-4 V.test strain. After incubation (2 h,
37uC) the viruses were plaque assayed for infectivity on MDBK cells. BoHV-4 titers are expressed relative to virus without antibody. The data presented
are the average 6 SEMs for 4 measurements and were analyzed by 2way ANOVA and Bonferroni posttests, ** p,0.01, *** p,0.001. Statistical
significance was only shown for O- treatment. Equivalent data were obtained in two further experiments.
doi:10.1371/journal.ppat.1002387.g005
transmembrane region. The red line indicates significative threshold. C. Prediction of O-glycosylation sites for the complete BoHV-4 V.test gp180
protein sequence using the NetOglyc 3.1 algorithm. The shaded regions indicate the signal peptide and transmembrane region. The red line indicates
significative threshold.
doi:10.1371/journal.ppat.1002387.g004
BoHV-4 gp180 Glycan Shield
PLoS Pathogens | www.plospathogens.org 7 November 2011 | Volume 7 | Issue 11 | e1002387located on gp120 itself [68], BoHV-4 gp180 protects other virion
glycoproteins in trans, rather than simply protecting itself in cis.
Studies on different viruses [69–70] suggest that protection of a
limited number of entry complexes from neutralization is probably
sufficient to preserve virion infectivity. In contrast, influence on
immunogenicity probably requires covering of all entry complexes
in order to render them invisible to the immune system. Gp180
does not hide all the vulnerable epitopes at the viral surface.
Indeed, even if gp180 hide most of the epitopes recognized by
mAb 16, 29, 33 and 35, some remains accessible at the surface of
WT or revertant virions (Figure 7). Moreover, infected cell debris
provides also certainly a source of uncovered antigens. It therefore
appears that gp180 influence virion antigenicity but not immuno-
genicity. Similarly, BoHV-4 gB N-term protects some vulnerable
epitopes, but its deletion does not result in an enhanced ability to
induce neutralizing antibody responses [71].
Another unusual feature of gp180 was the likely importance of
O-linked glycans for viral antibody evasion. In other viruses, most
protection against antibody seems to involve N-linked glycans
[41,72]. While BoHV-4 surface N-glycans are also involved in
antibody evasion (Figure 5B), this study strengthens the role of O-
glycans in neutralization evasion. O-linked glycans have also been
shown to protect MuHV-4 gB N-terminal ectodomain against
antibody [71]. Indeed, although MuHV-4 gB N-term confers
protection to some neutralization epitopes on gH/L, gB N-term is
itself a neutralization target [19,71]. However, depending on the
host cell, this part of gB can be largely protected against antibody
by O-linked glycans [71]. These glycans could also possibly assist
in protecting a neutralization epitope on gH/L. In BoHV-4, gB is
the only other described envelope protein that could bear O-
glycans. Indeed, gp180 and gB N-term contain respectively 122
and 33 predicted O-glycosylation sites [37]. These two proteins
and their glycans could therefore cooperate to render BoHV-4
particularly resistant to neutralization [73]. Similar N-terminal O-
glycans occur in the Herpes Simplex virus gC [74], but do not
have a known function. Because N-linked glycans are relatively
bulky, O-linked glycans may be better suited to protecting small or
linear glycoprotein domains while still allowing protein/protein
interactions. It seems with gp180 that protection by O-linked
glycans can also be ‘‘scaled up’’ for more extensive protection.
Because gp180 is likely to be part of a multi-protein complex, too
many N-glycans might disrupt important protein/protein interac-
tions. Another consideration is that glycans can on occasion be
targeted by the immune response [75]. In this context, glycan
diversity might be useful for a virus, and providing such diversity is
a potential function of the BoHV-4 Bo17 gene, which encodes a
mucin-type beta-1,6-N-acetylglucosaminyltransferase [76].
While glycans offer mainly protection in the natural setting, they
can also be artificially targeted for neutralization by carbohydrate
binding agents (CBAs) [77]. Evading CBAs would require a virus
to compromise its glycan shield, thereby promoting neutralization
by antibody [78]. As CBAs might be expected to elicit their own
antibody response after repeated dosing, thereby attenuating their
effect, anti-carbohydrate antibodies might be more useful in long-
term settings. This also opens the possibility of vaccination against
specific pathogen carbohydrates to target their glycan shields [79].
All together, our results suggest that BoHV-4 gp180 and, by
extension, its homologs in other gammaherpesviruses shield the
virus from immune recognition. This probably contributes to the
ineffectiveness of the antibody response against these viruses.
Materials and Methods
Ethics statement
The experiments, maintenance and care of rabbits complied
with the guidelines of the European Convention for the Protection
of Vertebrate Animals used for Experimental and other Scientific
Purposes (CETS nu 123). The protocol was approved by the
Committee on the Ethics of Animal Experiments of the University
of Lie `ge, Belgium (Permit Number: 1035). All efforts were made to
minimize suffering.
Cells and virus
Madin-Darby bovine kidney (MDBK) (ATCC CCL-22), Bovine
Turbinates (BT) (ATCC CRL-1390), Embryonic Bovine Trachea
(EBTr) (ATCC CCL-44), Embryonic Bovine Lung (EBL) (DSMZ
ACC-192), Bovine Macrophages (BOMAC) [80], bovine mam-
mary epithelial (MacT) [81] and EBL-NLS-Cre [30] cells were
Figure 6. Antigenicity of infected cells. MDBK cells were infected (2
PFU/cell, 36 h) with WT (solid black lines), Bo10 Del (red lines), Bo10 Rev
(dotted black lines), WT BAC (grey lines), Bo10 STOP (green lines) or
Bo10 STOP Rev (dotted grey lines) of BoHV-4 V.test, and then analyzed
by flow cytometry. The filled histogram shows uninfected cells. MAb 29
and 35 recognize gB, mAb 16 recognizes gL, and mAb 33 recognizes
gH/L. Fixed (PFA 4%, 4uC for 30 min) and permeabilized (saponin 0.1%)
cells were used as control of protein expression.
doi:10.1371/journal.ppat.1002387.g006
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containing 10% fetal calf serum (FCS), 2% Penicillin/Streptomy-
cin (Invitrogen) and 1% non Essential amino acids (Invitrogen).
Bovine PBMC were prepared as described elsewhere [82] and
cultured in RPMI Glutamax Medium containing 10% FCS, 2%
Penicillin/Streptomycin (Invitrogen), 1% Essential amino acids
(Invitrogen), 1 mM Sodium pyruvate, 25 mM HEPES and 50 mM
2-mercaptoethanol. The BoHV-4 V.test strain initially isolated
from a case of orchitis [83], the BoHV-4 WTeGFP, Bo10 Del and
Bo10 Rev strains [33] and the derived recombinant strain cloned
as an Bacterial Artificial Chromosome (BAC) [30], were used
throughout.
Plasmids
The coding sequence for BoHV-4 V.test gL amino acid residues
1-140 was amplified by PCR (Hi-Fidelity PCR kit, Roche
Diagnostics Ltd) with 5’ AvrII-restricted and 3’ NotI-restricted
primers. Similarly, the coding sequences for BoHV-4 V.test gB
amino acid residues 1–725 and gH amino acid residues 1–678
were amplified by PCR with 5’ XbaI-restricted and 3’ NotI-
restricted primers. These PCR products were cloned into the
XbaI/NotI sites of pBRAD, thereby attaching a C-terminal
glycosyl-phosphatidyl-inositol (GPI) membrane anchor [20],
generating gL-GPI, gB-GPI and gH-GPI expression plasmids.
Antibodies and reagents
The O-glycan specific lectin, jacalin, was purchased from
Vector Laboratories. For detection of gp180 on western blotting,
we used a rabbit monospecific polyserum raised against the C-
term end of the Bo10 encoded protein (anti-Bo10-c15) [33]. For
the neutralization experiments, we used sera of 4 different rabbits
infected intravenously with 10
8 PFU of the BoHV-4 V.test strain
and collected 63 days post inoculation. The mouse mAb M86
raised against the Gala1-3Gal epitope was purchased from Alexis
and used free of sodium azide as previously described [46]. Horse
serum was collected as a source of complement. The serum was
treated as described previously to preserve complement activity,
aliquoted and stored at 280uC [46].
Four mouse mAbs raised against BoHV-4 were also used in the
present study [84]. Their specificities were unraveled on 293T cells
transfected with the vectors encoding gB-GPI, gH-GPI or gL-GPI.
The epitopes depending on the gH-gL heterodimer were
reconstituted by co-expressing gH-GPI and gL-GPI. Briefly,
transfected 293T cells were fixed and permeabilized in Acetone
95% for 5 min and then stained with the different antibodies in
PBS containing 10% FCS (v/v). These antibodies were detected
with Alexa 488-coupled Goat anti-mouse IgG-specific antibodies
(Invitrogen). Nuclei were counterstained with DAPI (4,6-diami-
dino-2-phenylindole). Fluorescence was visualized with a Nikon
TE-2000 microscope and a Leica CCD camera.
Production of the BoHV-4 Bo10 STOP and Bo10 STOP Rev
strains
We disrupted the BoHV-4 V.test Bo10 coding sequence
(genomic coordinates 65,696 to 66,595, Genbank JN133502) by
introducing stop codons into the coding sequence for the Bo10
Figure 8. Sensitivity of Bo10- mutants to anti gL directed
neutralization. A. BoHV-4 WT V.test, Bo10 del, Bo10 Rev and Bo10
STOP virions were incubated with the gL-specific neutralizing mAb 16.
After incubation (2 h, 37uC) the viruses were plaque assayed for
infectivity on MDBK cells. BoHV-4 titers are expressed relative to virus
without antibody. The data presented are the average 6 SEMs for
triplicate measurements and were analyzed by 1way ANOVA and
Bonferroni posttests, ** p,0.01, *** p,0.001. B. BoHV-4 WT V.test, Bo10
del, Bo10 Rev and Bo10 STOP virions were incubated with increasing
amounts of the gL-specific neutralizing mAb 16, and then assayed for
infectivity on MDBK cells. BoHV-4 titers are expressed relative to virus
without antibody. Equivalent data were obtained in two further
experiments.
doi:10.1371/journal.ppat.1002387.g008
Figure 7. Antigenicity of purified virions. A. and B. Immuno-electron microscopy. Purified BoHV-4 WT V.test or Bo10 Del virions were processed
for immune-electron microscopy as described in Material and Methods. These samples were stained for gB with mAb 35 followed by secondary goat
anti-mouse IgG-10 nm gold labeled. Pictures of individual virions were then taken and gold particles were counted on each virion. The data
presented are the average 6 SEMs for 20 different virions and were analyzed by Student’s t-test, *** p,0.001 (A). Pictures of representative virions are
showed (B). C. Purified BoHV-4 WT V.test and Bo10 Del virus stocks were compared for gB content per PFU by immunoblotting for gB (with mAb 35)
as described in the Material and Methods. The position of a MM standard (in kDa) is shown on the left. D. Purified BoHV-4 WT V.test, Bo10 Del, Bo10
Rev, WT BAC, Bo10 STOP and Bo10 STOP Rev virions (10
5 PFU per lane) were compared for particles content per PFU by immunoblotting with anti
BoHV-4 V.test polyserum as described in the Material and Methods. The position of a MM standard (in kDa) is shown on the left. E. Antigenicity of
bound purified virions. MDBK cells were exposed to BoHV-4 V.test WT, Bo10 Del, Bo10 Rev, WT BAC, Bo10 STOP and Bo10 STOP Rev virions (20 PFU/
cell, 2 h, 4uC), then directly fixed with acetone 95%/water 5%. The cells were then stained for gB with mAb 29 and 35, for gL with mAb 16 and for gH/
gL with mAb 33. The pictures were taken with a confocal laser microscope. Images are shown with a pseudo-color glow scale (White, highest to black,
lowest intensity, blue represents overexposed pixels).
doi:10.1371/journal.ppat.1002387.g007
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produced using BAC cloning and prokaryotic recombination
technologies as described before [30]. The V.test BAC G plasmid
was used as parental plasmid [30]. The BoHV-4 V.test Bo10
STOP was produced using a two step galactokinase (galK)
positive/negative selection in bacteria [85]. The first recombina-
tion process (galK positive selection) consisted to introduce the
galK gene into the Bo10 coding sequence (genomic coordinate
65,760) resulting in the V.test BAC G Bo10 galK plasmid.
Recombination was achieved using the Bo10 galK cassette. It
consisted of the galK gene flanked by 50-bp sequences corre-
sponding to Bo10 regions (65,711-65,760 and 65,810-65,761 of
the BoHV-4 V.test strain genome). This cassette was produced by
PCR using pgalK vector [85] as template and Bo10-fwd-galK
5’agatctgtcatacattcaaattgcatgctttttatattcagcctcgcctgCCTGTTGA-
CAATTAATCATCGGCA 3’ and Bo10-rev-galK 5’ atacggtggtg-
gatgtgctggtgctgttgctggcagttaacccatatataTCAGCACTGTCCTG-
CTCCTT 3’ as forward and reverse primers, respectively (galK
sequences are indicated in capital letters, Bo10 start codon is in
bold). The second recombination process (galK negative selection)
consisted to replace the galK sequence by a Bo10 STOP cassette to
generate the BoHV-4V.testBo10 STOP plasmid.The Bo10 STOP
cassette consisted of a synthetic double strand DNA corresponding
to genomic coordinates 65,696 to 65,831 with the introduction
(genomic coordinate 65,761) of 36 nucleotides coding for in-frame
STOP codonsandrestrictionsites(Figure 1A). These 36 nucleotides
do not insert STOP codons in any of the 5 other frames of the
genome. The BoHV-4 V.test Bo10 STOP Rev plasmid was
produced similarly from BoHV-4 V.test Bo10 STOP plasmid. The
first recombination process (galK positive selection) was identical to
the one described above. The second recombination process (galK
negative selection) consisted to restore Bo10 to generate a revertant
plasmid. This cassette was produced by PCR using BoHV-4 V.test
genome as template and Bo10-rec-sens (genomic coordinates
65,183 to 65,207) and Bo10-rec-rev (genomic coordinates 67,278
to 67,257) as forward and reverse primers, respectively. Reconsti-
tution of infectious virus from BAC plasmids was obtained by
transfection in MDBK cells to obtain Bo10 STOP BAC and Bo10
STOP BAC Rev strains. To excise the BAC cassette, reconstituted
viruses were propagated in EBL-NLS-Cre cells expressing Cre
recombinase to generate the corresponding excised strain.
Southern blot
Southern blot analysis [82] of viral DNA digested with EcoRI
was performed with probe corresponding to genomic coordinates
65,696 to 66,595 of the BoHV-4 V.test genome.
Figure 9. Immunogenicity of BoHV-4 lacking gp180. Rabbit anti-BoHV-4 V.test WT antibody response. Groups consisting of 3 rabbits were
infected with 10
7 PFU of BoHV-4 WT V.test and Bo10 STOP excised strains. A. Sera were collected at different times post-infection and the titre of anti-
BoHV-4 antibodies was estimated by ELISA as described in the Material and Methods. Each value represents the mean +/- SD of the data obtained for
the three rabbits of each group. The serum of a mock infected rabbit was taken as control. The data were analyzed by 2way ANOVA and Bonferroni
posttests. No significative difference was observed between groups. B. Specific anti gB, gH and gL antibody responses were investigated by staining
unfixed 293T cells expressing GPI-linked forms of gL, the gB extracellular domain or the gH extracellular domain. These staining were performed with
sera collected 63 days post-infection. The data were analyzed by Student t-test. No significative difference was observed between WT and Bo10 STOP
sera. C. BoHV-4 WT V.test, Bo10 Del, Bo10 Rev and Bo10 STOP virions were incubated with sera of WT or Bo10 STOP infected rabbits collected 63 days
post-infection (3 sera per group). After incubation (2 h, 37uC) the viruses were plaque assayed for infectivity on MDBK cells. BoHV-4 titers are
expressed relative to virus without antibody. The data presented are the average 6 SEMs for 3 measurements and were analyzed by 2way ANOVA
and Bonferroni posttests. No significative difference was observed between WT and Bo10 STOP sera.
doi:10.1371/journal.ppat.1002387.g009
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BoHV-4 strains grown on MDBK cells were purified as follows.
Virions were harvested from infected MDBK cell supernatants by
ultracentrifugation (100,0006g, 2 h); infected-cell debris was then
removed by low-speed centrifugation (1,0006g, 10 min). Virions
were then centrifuged through a 20 to 50% (w/v) potassium
tartrate gradient in PBS (100,0006g, 2 h). Virions were recovered
from the gradient and finally washed and concentrated in PBS
(100,0006g, 2 h).
Western blot
Virions were lysed and denatured by heating (95uC, 5 min) in
SDS-PAGE sample buffer (31.25 mM Tris-HCl pH 6.8, 1% (w/v)
SDS, 12.5% (w/v) glycerol, 0.005% (w/v) Bromophenol Blue,
2.5% (v/v) 2-mercaptoethanol). Proteins were resolved by
electrophoresis on Mini-PROTEAN TGX (Tris-Glycine eXtend-
ed) precast 7.5% resolving gels (Bio-Rad) in SDS-PAGE running
buffer (25 mM Tris-base, 192 mM glycine, 0.1% (w/v) SDS) and
transferred to polyvinylidene difluoride membranes (Immobilon-P
transfer membrane, 0.45 mM pore size, Millipore). The mem-
branes were blocked with 3% non-fat milk in PBS/0.1% Tween-
20, and then incubated with anti-Bo10-c15 rabbit antibodies, mAb
35 or rabbit anti-BoHV-4 polyserum in the same buffer. Bound
antibodies were detected with horseradish peroxidase-conjugated
goat anti-rabbit IgG pAb or goat anti-mouse IgG pAb (Dako
Corporation), followed by washing in PBS/0.1% Tween-20,
development with ECL substrate (GEHealthcare) and exposure
to X-ray film.
Animals
Specific-pathogen-free New-Zealand white rabbits were used
throughout this study. Rabbits were inoculated intravenously with
purified stocks of the different viral strains. In one experiment we
infected rabbits with WT, Bo10 Del or Bo10 Rev strains (10
8
Figure 10. Glycans on BoHV-4 gp180 allow virus neutralization. A. Sensitivity of WT, Bo10 Del and Bo10 Rev strains to Jacalin mediated
neutralization. BoHV-4 WT V.test, Bo10 Del and Bo10 Rev virions were incubated with increasing amounts of O-glycan specific lectin jacalin (1 h, 37uC)
and then assayed for infectivity on MDBK cells. BoHV-4 titers are expressed relative to virus without lectin. The data presented are the average 6
SEMs for 3 measurements and were analyzed by 2way ANOVA and Bonferroni posttests, *** p,0.001. B. Sensitivity to anti-Gal antibodies induced
complement dependent neutralization of BoHV-4 WT, Bo10 Del, Bo10 Rev and Bo10 STOP strains. Virions of the different strains derived from MDBK
cells were assayed for their sensitivity to neutralization by horse serum supplemented with increasing amounts of mAb M86 raised against Gala1-
3Gal. Horse sera (heat inactivated or not by incubation at 56uC for 30 min) were tested at the final concentration of 10% (vol/vol). After incubation
(2 h, 37uC) the viruses were plaque assayed for infectivity on MDBK cells. BoHV-4 titers are expressed relative to virus without antibody.
doi:10.1371/journal.ppat.1002387.g010
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STOP strains (10
7 PFU). At the end of the experiment, rabbits
were euthanized and a necropsy examination was performed
during which the spleen was collected.
Isolation of peripheral blood mononuclear cells and
preparation of spleen cell suspension
Blood samples were collected and PBMC were separated by
Ficoll (Ficoll-Paque Plus, GE Healthcare) density gradient as
described previously [86]. Immediately after euthanasia, spleen
was removed and half-part of it was homogenized using a tissue
grinder (VWR), passed through a stainless steel sieve and washed
in FCS-free MEM before further analyses.
Viral genome detection by Real time-PCR
DNA was purified from the spleen and PBMC using the QIAamp
DNA Mini kit (Qiagen). Real-time PCR was performed as described
elsewhere [87]. A 103 bp fragment corresponding to BoHV-4 ORF8
was amplified with the forward primer 8startfw (5’- CAAATAGTT-
CATTAGCTGCCTCTCC -3’) and the reverse primer 8middlerev
(5’- TCATCAGTAACAGTTGGAATAGTGG -3’) in the presence
of the fluorescent probe 5’-FAM-AACACGTCAACA AGCAAGC-
CATCCACTG-TAMRA-3’. pGEM-T easy containing BoHV-4 gB
ORF was used to establish standard curves. PCR amplifications and
fluorescence reactions were carried out in a iCycler system (Bio-Rad)
under the following conditions: initial activation of the Taq
polymerase (Bio-Rad) at 94uC for 5 min followed by 50 cycles at
94uCf o r1mi n ,5 0c y c l e sa t5 1 uC for 30 sec and 50 cycles at 72uCfo r
1m i n .
Virus detection by infectious centre assay
Viral detection in spleen cell suspension was assayed by
infectious centre assay (ICA) as follows. 5.10
5 MDBK cells grown
in 6 well cluster dishes (Becton Dickinson) were co-cultured for 7
days at 37uC with spleen cells in MEM containing 10% FCS, 2%
PS, 0.6% CMC and 5.10
25Mo fb-mercaptoethanol (Merck). Cells
were then fixed and stained with mAb 35 for indirect
immunofluorescent detection of intracellular viral antigen as
described previously [33]. Fluorescence was then visualized with
a TE2000-S Nikon and a Leica DC300F CCD camera system.
Oligosaccharide digestion
All reagents were obtained from New England BioLabs. For
SDS-PAGE analysis, samples were denatured in Glycoprotein
Denaturing Buffer (0.5% SDS, 40 mM DTT) for 10 min at 100uC
and then digested for 3 h at 37uC with 250 NEB units PNGase F
and/or 250 NEB units of neuraminidase, b1-4 Galactosidase, O-
glycanase in G7 reaction buffer (50 mM sodium phosphate,
pH 7.5) with 1% NP-40. Reactions were stopped by the addition
of Laemmli sample buffer and proteins were analyzed by
immunoblotting as described below. For neutralization assays,
N- or O-linked glycans were removed with the same enzymes, but
without reduction or denaturation. Thus, intact virions were
incubated with the different enzymes (3 h, 37uC) in PBS/5% fetal
calf serum buffered to pH 6.
Flow cytometry
For cell surface staining, cells infected by the different virus
strains (2 PFU/cell, 36 h) were washed in PBS and analyzed
directly for green channel fluorescence [71]. For intracellular
staining, cells were fixed in 1% paraformaldehyde (30 min at room
temperature) and then permeabilized with 0.1% saponin. Cells
were incubated (1 h, 4uC) with the different mAbs specific for
BoHV-4 glycoproteins followed by Alexa 633-conjugated goat
anti-mouse pAb (Invitrogen). Cells were then washed and analyzed
on a FACSAria cytometer (Becton Dickinson).
Immunogold labeling of virions
Copper grids of 400 mesh (Agar Scientific Ltd) were incubated
for 10 min with 2% Alcian blue 8G solution (Gurr Microscopy
Materials, BHD) to add positive charges. After washing, purified
virions (10
8 PFU/ml) were adsorbed to the grids for 10 min. Non-
specific interactions were blocked by incubation of the grids for
15 min in PBS containing 0.1% (w/v) cold water fish skin gelatin
(CWFG, Aurion) and 5% (w/v) goat serum (Invitrogen). This
solution was also used for further incubation and washes.
Immunogold labeling was performed by incubation of the grids
with mAb 35 as primary antibody for 60 min at room
temperature. After washing with PBS and incubation in PBS
0.1% CWFG 5% goat serum for 5 min, the grids were incubated
with Goat anti-mouse IgG-10 nm gold labeled conjugate (diluted
1:50, BBInternational) as secondary antibody for 60 min at RT. A
final incubation step was performed in 2% uranyl acetate solution
for 10 sec (Agar Scientific). Immunogold stained virions were
observed using a transmission electron microscope (FEI, TEcnai
Biotwin). Micrographs of virion were acquired for at least 20
individual virions per strain.
Indirect immunofluorescent staining of bound virions
Infected cells (20 PFU/cell, 2 h, 4uC) were fixed in cold Acetone
95% for 5 min on ice. Immunofluorescent staining (incubation
and washes) was performed in PBS containing 10% FCS (v/v).
Samples were incubated at RT for 45 min with the different mAbs
raised against BoHV-4 glycoproteins. After three washes, samples
were incubated at RT for 45 min with Alexa Fluor 488 or Alexa
Fluor 568 goat anti-mouse IgG (2 mg/ml; Invitrogen). Images were
acquired on a Leica TCS SP confocal laser scanning microscope
with settings specific for Alexa Fluor 488 or Alexa Fluor 568.
Acquisition settings (PMT voltage and offset) were kept identical
between slides stained with the same antibodies.
Quantification of anti-BoHV-4 antibodies by ELISA
Nunc Maxisorp ELISA plates (Nalgene Nunc) were coated for
18 h at 37uC with 0.1% Tween 20-disrupted BoHV-4 virions (2.10
6
PFU/well), blocked in PBS/0.1% Tween-20/3% BSA, and
incubated with rabbit sera (diluted 1/300 in PBS/0.1% Tween-20/
3% BSA). Bound antibodies weredetected with Alkaline Phosphatase
conjugated goat anti-rabbit Ig polyclonal antibody (Sigma). Washing
were performed with PBS/0.1% Tween-20/3% BSA. p-Nitrophe-
nylphosphate (Sigma) was used as substrate and absorbance was read
at 405 nm using a Benchmark ELISA plate reader (Thermo).
Nucleotide sequence accession numbers
Sequence data reported here have been deposited in the
GenBank database under the following accession numbers:
BoHV-4 V.test Long Unique region (JN133502).
Supporting Information
Figure S1 Neutralization of the BoHV-4 gp180 deficient
virions on various cell types. BoHV-4 V.test WTeGFP and
Bo10 Del virions were incubated with serum of a rabbit infected
with BoHV-4 V.test strain. After incubation (2h, 37uC) the viruses
were used to infect MDBK, BT, EBTr, EBL, BOMAC and MacT
cells. BoHV-4 titers are expressed relative to virus without
antibody.
(TIF)
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BoHV-4 infectivity. Intact BoHV-4 V.test WT virions were
deglycosylated without denaturation as described in the Material
and Methods. N-, PNGase F; O-, neuraminidase + b1-4
Galactosidase + O-glycanase; NO-, PNGase F + neuraminidase
+ b1-4 Galactosidase + O-glycanase. After deglycosylation
treatment, virion samples were titered and these titers were
expressed as percentage of the titers measured before deglycosyla-
tion.
(TIF)
Figure S3 Identification of the targets of mAbs 16, 29
and 33. In order to map mAb recognition, 293T cells were
transfected with the gB or gH extracellular domains or the entire
gL fused to a GPI membrane anchor resulting in gB-GPI, gH-GPI
and gL-GPI respectively. To reconstitute epitopes depending on
the gH-gL hetrodimer, we cotransfected the cells with plasmids
encoding gH-GPI and gL-GPI. Forty-eight hours after transfec-
tion, the cells were fixed and stained with the different mAbs as
indicated.
(TIF)
Figure S4 Immunoelectron microscopy of virions. Puri-
fied BoHV-4 WT V.test or Bo10 Del virions were processed for
immuno-electron microscopy as described in the Material and
Methods. These samples were stained for gB with mAb 35
followed by secondary goat anti-mouse IgG-10 nm gold labeled.
Pictures of individual virions were then taken. Pictures of 5
representative virions per strain are showed.
(TIF)
Figure S5 Sensitivity of the Bo10 STOP strain to anti gL
directed neutralization. A. and B. BoHV-4 V.test WT BAC,
Bo10 STOP and Bo10 STOP Rev virions were incubated with the
gL-specific neutralizing mAb 16 (100 mg/mL). After incubation
(2h, 37uC) the viruses were plaque assayed for infectivity on either
MDBK cells (A) or EBL cells (B). After 4 days of incubation, the
plates were fixed and the plaques were counted. BoHV-4 titers are
expressed relative to virus without antibody. The data presented
are the average 6 SEMs for triplicate measurements and were
analyzed by 1way ANOVA and Bonferroni posttests, * p,0.05,
** p,0.01, *** p,0.001.
(TIF)
Table S1 Bo10 sequences divergences among BoHV-4
strains. Nucleotide and amino acid sequences divergences of
Bo10 genes from 9 BoHV-4 strains were determined using
CLUSTALw. Values above and below the diagonal refer to
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